key: cord-0751361-ywbj9bme authors: Singh, S.; Maurya, R. P.; Singh, R. K. title: 'Trained immunity' from Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes date: 2020-07-14 journal: nan DOI: 10.1101/2020.07.11.20151308 sha: 030a53517e43dbf6b4ac2737d8c200cf66d9b205 doc_id: 751361 cord_uid: ywbj9bme Protective variables for COVID-19 are unknown. 'Trained immunity' of the populace as a result of BCG policy implementation and coverage had been suggested to be one of the factors responsible for the differential impact of COVID-19 on different countries. Several trials are underway to evaluate the potential protective role of BCG vaccination in COVID-19. However, the lack of clarity on the use of appropriate controls concerning 'trained immunity' has been a cause of concern leading to more confusion as exemplified by a recently concluded trial in Israel that failed to find any correlation. Whereas, when we analyze the COVID-19 data of European countries without any mandatory BCG vaccination policy but with similar age distribution, comparable confounding variables, and the stage of the pandemic, the prevalence of Mycobacterium spp.(including BCG vaccine) exposure of the populations is consistently negatively correlated with COVID-19 infections per million population at all the time points evaluated [r(20): -0.5511 to -0.6338; p-value: 0.0118 to 0.0027]. The results indicate that the on-going and future studies evaluating the effect of BCG vaccination on COVID-19 outcomes should consider the inclusion of 'controls' for underlying 'trained immunity' prevalence or that resulting from the intervention (BCG vaccine) in such trials to arrive at more dependable conclusions. The implementation of mandatory BCG vaccination policy by countries in the past and the BCG immunization coverage of the populations have been associated with the lower COVID-19 cases and mortality. However, the confounding variables among countries such as the stage of the outbreak, population age distribution, health infrastructure, management practices, the testing/screening, and reporting guidelines, etc. make the comparisons tenuous [1, 2] . Since the 'trained immunity' status conferred by BCG vaccination in childhood wanes rapidly within years in the absence of 'booster' Mycobacterium spp. exposures [3] , the prevalent actual 'trained immunity' of the population could be a better evaluable predictive parameter of populations' response to COVID-19 infections, if any, rather than relying on BCG vaccination in the childhood or the national policy as recently reported in JAMA by Hamiel and colleagues [4] . Tuberculin Sensitivity Test (TST) combined with Interferon Gamma Release Assay (IGRA) is generally used to assess the presence of immune response against Mycobacteria spp. (environmental or BCG vaccine). In the absence of IGRA positivity, it is referred to as 'Latent Tuberculosis Infection' (LTBI) broadly signifying the absence of tuberculosis disease but the presence of active immunity against the pathogen. As about 1-5% of the LTBI positive individuals could develop Tuberculosis in their lifetime due to either subsequent infection after the 'trained immunity' wanes or when the immunity is compromised for any reason (e.g., HIV infection, cancer, immunosuppressant therapy) this 'LTBI' nomenclature has been retained though not without causing confusion and general aversion of its use as a measure of 'trained immunity'. We reason, if indeed 'trained immunity' status could help reduce infections in a population, the estimated prevalence of Latent Tuberculosis Infection (%LTBI) of resident populations would more closely correlate with COVID-19 infection and mortality rates. The European countries with no mandatory BCG vaccination policy, comparable medical infrastructure, mobility, exposure to SARS-CoV-2, and other confounding variables, currently at a similar stage of epidemic-curve but differential 'trained immunity' status as reflected in %LTBI offer an excellent opportunity to evaluate such assertion. The populations from 20 European countries with a differential prevalence of %LTBI [5] (published by the 'Institute for Health Metrics and Evaluation (IHME)' 2018) and comparable confounding variables, including the stage of the pandemic (infections peak) ( Table 1) are assessed for any correlation with COVID-19 cases and mortality data without any exclusion criterion (e.g., age, sex, ethnicity) at different stages, i.e., 8 April, 12 May, and 26 May 2020 from https://www.worldometers.info/coronavirus/ [6] of the ongoing pandemic, as done previously for Vitamin D [7] . . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.11.20151308 doi: medRxiv preprint The 'trained immunity' prevalence correlates of the populations (i.e., %LTBI) indicates a strong correlation with COVID-19 infections ( Table 1) Table 1) , similar to previously observed by us [1] . See Figure 1 for the potential predictive correlative inference of the data on May 26, 2020. In the differentially 'trained immunity' populations of European countries, the COVID-19 cases per million population negatively correlate with the %LTBI prevalence of the population at each analyzed stage of the pandemic. However, an insignificant negative correlation is observed with deaths per million populations as would be expected with individuals/populations without sufficient 'trained immunity' being vulnerable to getting infected. The strength of the assertion lies in the large affected study population, i.e., 1,413,367 COVID-19 patients (about 25% of total worldwide on 26.05.2020) [6] ; representing 20 different 'trained immunity' level (%LTBI prevalence) groups/populations from countries without a mandatory BCG vaccination policy; comparable health infrastructure, screening and reporting guidelines along with similar age and sex distribution and other confounding variables. The correlation analysis consistently indicates the same association at all 3 different time points of the epidemic curve evaluated. In the light of observation presented, it may be suggested that ongoing trials/studies evaluating the effect of BCG vaccination on COVID-19 infections [2] , including the one recently concluded in Israel and reported in JAMA [4] could provide more objective conclusions on inclusions of the estimates about the 'trained immunity' of study participants/ populations. Dedicated studies using the available patient records or epidemiological surveys backed by followup clinical trials with suitable controls for the 'trained immunity' correlates are advisable to assess the biological significance of the observed correlation and arrive at a more meaningful conclusion about BCG vaccination conferred 'trained immunity' and COVID-19 control. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.11.20151308 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. . https://doi.org/10.1101/2020.07.11.20151308 doi: medRxiv preprint Not Reduce Covid-19 Mortality Rates BCG-induced trained immunity: can it offer protection against COVID-19? BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA-Indian adults SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults Global Burden of Disease Collaborative Network COVID-19 Coronavirus Pandemic Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak The general funding support by Banaras Hindu University to the laboratory of Pop.